Precision Neuroscience Expands Executive Team as Brain–Computer Interface Industry Rapidly Advances
23 Julho 2024 - 10:00AM
Precision Neuroscience Corporation (Precision), a leader in
developing brain–computer interface technology to restore function
and autonomy for millions of people with neurological disorders,
today announced the expansion of its executive team with the
addition of Jayme Strauss, RN, MSN, MBA, as Chief Clinical and
Commercial Officer and Mike Kaswan as Chief Financial Officer. The
two new hires bring decades of experience in driving growth at
innovative health companies and will play a pivotal role in the
commercialization of Precision’s brain–computer interface (BCI)
technology.
Jayme Strauss will lead Precision’s efforts to establish
research partnerships with hospitals and health systems throughout
the U.S. and to drive adoption of the company’s first commercial
product. Before joining Precision, she served as Chief Clinical
Officer at Viz.ai, a pioneering healthcare AI company, where she
grew the company’s customer base from a handful of hospitals to
over one thousand, through strategies that generated real-world
evidence showing the effectiveness of AI in improving patient
outcomes. She also worked to secure the first-ever AI New
Technology Add on Payment (NTAP) from the Centers for Medicare
& Medicaid Services. Strauss was trained as a neuro ICU nurse
and spent a decade as a hospital executive, building renowned
neuroscience and stroke systems of care at Baptist Health South
Florida in Miami and Piedmont Healthcare in Georgia. She holds an
MSN and MBA from Grand Canyon University and received her BSN at
Cedar Crest College.
Mike Kaswan brings over 30 years of financial leadership
experience in healthcare to his role as CFO at Precision. Kaswan
has held numerous C-suite roles at high-growth life science
companies. Most recently, he served as the CFO at Orchestra BioMed
Holdings (NASDAQ: OBIO), which he helped take public in 2023. He
also co-founded three successful healthcare businesses: Georgia
Veterinary Specialists (now part of BluePearl Veterinary Partners),
one of the first private veterinary specialty hospitals in the
country; Lumenos (now part of Wellpoint), one of the first consumer
driven healthcare companies; and Persante Health Care, a leading
provider of sleep and balance diagnostics and treatments.
Additionally, Kaswan was a healthcare-focused venture capital
investor for more than ten years. He holds a B.S. in Commerce from
the University of Virginia and an MBA from Harvard Business
School.
“As Precision moves closer to commercialization, we’re focussing
on recruiting exceptional talent with the vision and skill to
support the next chapter of the company’s growth,” Michael Mager,
CEO of Precision Neuroscience, said. “Both Jayme and Mike bring
invaluable experience to our team as we work to bring this
technology to the clinic in coming years.”
Precision is a leader in the development of brain implants,
called brain–computer interfaces, for medical use. Since its
founding in 2021, the company has developed its core product, a
high resolution cortical surface array called the Layer 7 Cortical
Interface, and acquired a proprietary facility for commercial-scale
manufacturing. The company is currently testing its device in
patients through research collaborations with West Virginia
University’s Rockefeller Neuroscience Institute, Perelman School of
Medicine (Penn Medicine), and Mount Sinai Health System in New
York, and it is set to expand its research partnerships in the
coming year.
About Precision:Precision Neuroscience is
working to provide breakthrough treatments for the millions of
people worldwide suffering from neurological illnesses. The company
is building the only brain–computer interface designed to be
minimally invasive, safely removable, and capable of processing
large amounts of data. To learn more about how Precision is
connecting human intelligence and artificial intelligence, visit
www.precisionneuro.io.
Contact: media@precisionneuro.io
Orchestra BioMed (NASDAQ:OBIO)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Orchestra BioMed (NASDAQ:OBIO)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024